Labcorp Holdings (LH) has demonstrated impressive performance in various areas. LH's stock growth stayed steady while it continued to make solid total returns. While there's decreased growth outlook in its contract research unit triggered by a biotech funding crunch, it did not deter LH's overall growth. Q3 2025 earnings showed strong revenue growth and saw an upswing of 8.1% since the last earnings report. LH has made innovative steps by launching an FDA-approved Alzheimer's diagnostic blood test and introducing an AI tool, the Test Finder, to simplify lab test search. The company executed an impactful move in the oncology field with the acquisition of select BioReference Health assets. However, there are signs of slowing growth and margin pressure that shareholders should be cognizant of. Despite a solid year of performance, Labcorp's stock took a hit, though reasons behind the fall weren't detailed. The healthcare giant announced executive retirements and an appointment to its Board of Directors. Furthermore, LH declared a quarterly dividend of $0.72 and completed share buybacks, reinforcing its position as a top growth stock.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Tue, 16 Dec 2025 02:02:23 GMT -
Rating 7
- Innovation 4
- Information 6
- Rumor 2
